RecruitingNCT06562400

Searching for Novel Therapeutic Approaches in Migraine Patients Resistant to Treatments

Unraveling the Spectrum of Migraine Resistant to Treatments: Searching for Novel Biological PHEnotypes and theRApeutic Approaches (SPHERA Project)


Sponsor

IRCCS National Neurological Institute "C. Mondino" Foundation

Enrollment

45 participants

Start Date

May 10, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

Primary working hypothesis is that NON-responders to mAbs bear a dysfunction of the endocannabidiome system (eCBome), as suggested by pre-clinical and clinical data by our group. They will be identified as patients showing a reduction of monthly migraine days \< 50% after three months of treatment. The clinical, biochemical and neurofunctional impact of novel therapeutic approaches expected to interfere with eCBome will be evaluated in NON-responder patients


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria5

  • male and female patients aged 18 to 75 years
  • diagnosis of episodic migraine or chronic migraine according to ICHD-3 criteria
  • for episodic migraine: 8-14 monthly migraine days in the previous 3 months
  • diagnosis of resistant migraine, defined by having failed at least 3 classes of migraine preventatives and suffer from at least 8 debilitating monthly headache days for at least 3 consecutive months
  • patients naive to CGRP targeting treatments

Exclusion Criteria6

  • history of major psychiatric or other neurological conditions
  • diagnosis of other primary or secondary headache disorders (only sporadic tension-type headache is allowed if the patients can clearly differentiate between the 2 types of headaches)
  • clinically significant medical conditions
  • chronic pain conditions
  • alcohol and/or drug abuse
  • pregnancy or lactation

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTPalmitoyl ethanolamide

PEA supplementation (600mg twice a day for three months)

BEHAVIORALKetogenic diet

Diet characterized by the following percentages of macronutrients: 65% fat, 27% protein and 8% carbohydrates


Locations(1)

Headache Science & Neurorehabilitation Unit

Pavia, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06562400


Related Trials